Harbour BioMed Enters Long-Term Strategic Collaboration with Lannacheng to Advance Next-Generation Radionuclide Drug Conjugates
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 29 2025
0mins
Source: Yahoo Finance
- Strategic Collaboration: Harbour BioMed has established a long-term strategic partnership with Lannacheng to jointly advance the development of next-generation radionuclide drug conjugates (RDCs), aiming to enhance the precision and efficacy of cancer therapies.
- Technological Advantage: Harbour BioMed's Harbour Mice® platform generates fully human monoclonal antibodies, and when combined with Lannacheng's radiopharmaceutical R&D capabilities, is expected to significantly improve targeted drug delivery efficiency while reducing drug-related toxicity.
- Market Potential: RDCs deliver radionuclides directly to tumor lesions via tumor antigen-specific ligands, effectively minimizing damage to surrounding healthy tissues, and hold potential for overcoming tumor heterogeneity and drug resistance, indicating a broad market outlook.
- Innovative Integration: This collaboration will integrate both parties' strengths in antibody discovery and radiopharmaceutical development, accelerating the creation of safer and more effective cancer treatment solutions, thereby bringing new hope to patients worldwide.
Analyst Views on 02142
Wall Street analysts forecast 02142 stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for 02142 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 14.380
Low
Averages
High
Current: 14.380
Low
Averages
High
No data
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
